Grand Pharmaceutical GroupCGPHF 86 EBIT per Share is $0.06 as of Dec. 2025. GuruFocus rates CGPHF with a GF Score™ of 86/100. The stock has 6 warning signs investors should review. Among 810 Drug Manufacturers companies, Grand Pharmaceutical Group ranks worse than 80.62% on this metric.
Grand Pharmaceutical Group's EBIT per Share for the
six
months ended in Dec. 2025 was $0.01.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.06.
During the past 12 months, the average EBIT per Share Growth Rate of Grand Pharmaceutical Group was -22.40% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -14.00% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 15.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Grand Pharmaceutical Group's EBIT per Share or its related term are showing as below:
CGPHF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -14 Med: 23.95 Max: 79.3
Current: -14
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Grand Pharmaceutical Group was 79.30% per year. The lowest was -14.00% per year. And the median was 23.95% per year.
CGPHF's 3-Year EBIT Growth Rate is ranked worse than 80.62% of 810
companies
in the Drug Manufacturers industry
Industry Median: 7.55
vs CGPHF: -14.00
Grand Pharmaceutical Group (OTCPK:CGPHF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Grand Pharmaceutical Group EBIT per Share Related Terms
Grand Pharmaceutical Group EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.06
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grand Pharmaceutical Group (CGPHF) has a EBIT per Share of $0.06 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Grand Pharmaceutical Group and its competitors. According to the industry distribution chart, Grand Pharmaceutical Group ranks #653 out of 810 companies in the Drug Manufacturers industry, placing it in the top 80.6%.
Is Grand Pharmaceutical Group's EBIT per Share too high?
Grand Pharmaceutical Group's current EBIT per Share is $0.06. The Drug Manufacturers industry median EBIT per Share is 7.55. Grand Pharmaceutical Group's value of $0.06 is 99.2% below this industry median. Based on the distribution chart, Grand Pharmaceutical Group ranks #653 out of 810 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Grand Pharmaceutical Group has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Grand Pharmaceutical Group ranks #653 out of 810 companies for EBIT per Share. This places Grand Pharmaceutical Group in the lower half of its industry. The industry median EBIT per Share is 7.55. Grand Pharmaceutical Group's value of $0.06 is 99.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.55, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grand Pharmaceutical Group's current EBIT per Share of $0.06 is 99.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Grand Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grand Pharmaceutical Group's current EBIT per Share is $0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Grand Pharmaceutical Group (CGPHF) has a current EBIT per Share of $0.06. The current EBIT per Share is $0.06 and 99.2% below the Drug Manufacturers industry median of 7.55. Grand Pharmaceutical Group's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Grand Pharmaceutical Group (CGPHF), the current EBIT per Share is $0.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGPHF has been successfully added to your 